eligibility_summary
Include: ≥18 with relapsed/refractory MM, 1–3 prior lines incl anti‑CD38, PI, IMiD, and BCMA CAR‑T (or ineligible/deferred), measurable disease, ECOG 0–2, adequate blood counts, renal CrCl ≥30, hepatic, prior AEs ≤1, able to receive outpatient elranatamab (≤30 min from site, reliable caregiver), no prior grade 3–4 CRS/ICANS, negative pregnancy test. Exclude: other plasma cell disorders, CNS MM, active cancer/infection/autoimmune, recent therapy/radiation/transplant, immunosuppression, major cardiac/comorbidities, neuropathy ≥2, GBS, pregnancy/lactation, hypersensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Elranatamab (Elrexfio) monotherapy. Type: Subcutaneous bispecific T‑cell–engaging monoclonal antibody (immunotherapy). Mechanism of action: Binds BCMA (TNFRSF17) on malignant plasma cells and CD3 on T cells, forming an immune synapse that activates T cells and redirects cytotoxicity (perforin/granzyme) to kill BCMA+ myeloma cells, depletes BCMA-expressing plasma cells and can trigger cytokine release. Targets: Cells—BCMA+ myeloma/plasma cells, CD3+ T lymphocytes. Pathways—BCMA signaling on plasma cells, TCR/CD3-mediated T‑cell activation and cytolytic pathways within the bone marrow microenvironment. Trial notes: Phase II, single‑arm, MRD‑adapted design with treatment-free observation after ≥12 months of sustained MRD negativity in relapsed/refractory multiple myeloma.